Table 2 Treatment modalities of COPD patients
From: Value of serum and induced sputum surfactant protein-D in chronic obstructive pulmonary disease
Group 2 (stage 1 and 2 COPD patients) | Group 3 (stage 3 and 4 COPD patients) | |
|---|---|---|
(n = 20) | (n = 20) | |
Short acting β2 agonist | 6 | 12 |
Long acting β2 agonist | 12 | 18 |
Long acting anticholinergic | 7 | 15 |
Inhaler steroid | 6 | 18 |
N-acetyl systein | 2 | 7 |
Long term oxygen therapy | 2 | 10 |
Pulmoner rehabilitation | 0 | 7 |